个人简介：
李彬博士现任礼来亚洲基金风险合伙人，之前在复星凯特任研发与商务拓展负责人，再之前在艾伯维任亚太区探索与评估总监，负责日本及亚太区对外合作的发现与评估工作。2015年七月加入全球探索与评估团队之前，李博士任艾伯维（中国）研发中心研发总监及负责人，领导该中心专注于多领域疾病包括糖尿病肾病的临床前新药研发工作。李博士于2008年9月加入雅培（上海）研发中心任研发总监，组建雅培上海研发中心，致力于几个重要疾病领域如免疫，肾脏病，和中枢神经系统疾病的新药研究开发。此前于2007年3月加入睿智化学，参与组建了生物部并担任副总裁。回国前16年间，李博士在美国罗氏，辉瑞，ANADYS及XCEPTOR等公司担任研究员到总监等不同职位，从事及领导多种疾病领域的新药研发课题，以及开发药物筛选新技术平台（如ATLAS高通量新药筛选技术）。李博士1982年毕业于兰州大学化学系，1986年在爱荷华州立大学获硕士学位，1990年在宾夕法尼亚州立大学获博士学位。李博士有二十多年的新药研发经验，从事过多种疾病领域的小分子新药开发研究。
Dr. Bin Li is currently a Venture Partner at Lilly Asia Ventures. Prop to that, he served as Head of Research and BD at Fosun Kite and prior to that, Director, Search & Evaluation, JAPAC at AbbVie in Shanghai, responsible for search and evaluation of partnership opportunities in key therapeutic areas of immunology, oncology, neuroscience, and liver diseases. Prior to joining global S&E team in July 2015, he was site head of AbbVie China R&D Center in Shanghai which focuses on pre-clinical drug discovery in several therapeutic disease areas including chronic kidney diseases. Dr. Li joined Abbott R&D Center, Shanghai in September of 2008 to head the center and carry out drug discovery research in several key therapeutic areas, and continued to head the center following separation of pharmaceutical business and formation of AbbVie. Prior to Abbott, Dr. Li was Vice President, Service Biology at ChemPartner to build and lead the service biology division. Before returning to Shanghai, he spent 16 years in US pharmaceutical and biotech companies, including Roche, Pfizer, Anadys, and Xceptor, with various titles from Research Scientist to Director to lead and support drug discovery research as well as drug screening and lead discovery technologies such as ATLAS, an affinity-based high throughput screening platform for protein ligand identification. Dr. Li received his B.S. from Lanzhou University in China in 1982, M.S. from Iowa State University in 1986, and Ph.D. from Penn State University in 1990. Dr. Li has more than 25 years of drug discovery experience in various therapeutic disease areas.
公司简介：
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.